Travere Therapeutics (TVTX) Short term Debt (2018 - 2025)

Travere Therapeutics' Short term Debt history runs 8 years deep, the most recent figure standing at $68.8 million for Q2 2025.

• Quarterly Short term Debt changed N/A year-over-year to $68.8 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $68.8 million (changed N/A YoY) and the FY2024 annual result came in at $68.7 million, changed N/A from the prior year.
• Short term Debt was $68.8 million for Q2 2025 at Travere Therapeutics, roughly flat from $68.8 million in the prior quarter.
• Across five years, Short term Debt topped out at $68.8 million in Q2 2025 and bottomed at $6.9 million in Q1 2023.
• A 5-year average of $29.6 million and a median of $7.4 million in 2021 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2021 — Short term Debt sank 57.47% — and 2022, when it retreated 5.41%.
• Travere Therapeutics' Short term Debt stood at $7.4 million in 2021, then slipped by 5.41% to $7.0 million in 2022, then slipped by 1.43% to $6.9 million in 2023, then jumped by 895.33% to $68.7 million in 2024, then advanced by 0.23% to $68.8 million in 2025.
• Business Quant data shows TVTX's Short term Debt at $68.8 million in Q2 2025, $68.8 million in Q1 2025, and $68.7 million in Q4 2024.